Skip to main content

Adamant Health, headquartered in Kuopio, is partnering with German pharmaceutical and healthcare producer Gerresheimer to improve the quality of life for people with Parkinson’s disease. The Finnish startup has raised €2.2 million in seed funding from its existing investors Voima Ventures and Cor Group, as well as the German company and several angel investors. This collaboration will pave the way for Adamant Health’s technology to reach new markets to help more people with movement disorders.

Founded in 2020 as a spin-off from the University of Eastern Finland, the startup provides analytics services that are advanced services for clinical use, but can also be easily used in a home environment. This portable and cost-effective technology collects accurate data from patients, allowing them to be monitored and come to an evidence-based conclusion faster.

Finnish health tech start-up Adamant Health partners with German medical technology company Gerresheimer to improve care for people with Parkinson’s disease

Adamant Health’s technology, using electromyography, is the first in the world to reliably measure the impact of drugs on patients’ motor symptoms, also outside of clinic visits, in daily life. Doctors can use technology to decide on more targeted drugs, and in addition, pharmaceutical companies can develop better drugs because they can now get real data from the field.

German medical technology company Gerresheimer is investing in a Finnish startup to enable measurements in the daily lives of people with Parkinson’s disease. Adamant Health and Gerresheimer have great strategic synergies in bringing new and game-changing solutions to provide better days for people with Parkinson’s disease. Adamant Health obtains funding to further develop its Parkinson’s disease measurement and analysis service and enter new markets. In addition to Gerresheimer, existing investors Voima Ventures and Cor Group, as well as several angel investors, are participating in the round.

Inflexible Health, Paulus Carpelan“With this funding, we are securing the further development of Adamant Health’s solution and our ability to introduce it to new markets. Our measurement and analysis service – including CE marked analysis technology – aims to improve the daily lives of people with Parkinson’s disease.

The service allows physicians to individualize their treatment based on detailed visibility into their patient’s symptoms and overall situation.” said Paulus Carpelan, CEO, Adamant Health Ltd. “We are excited and look forward to collaborating with Gerresheimer as part of our shared vision to improve healthcare outcomes for people with Parkinson’s disease.

Adamant Health’s analysis technology uses wearable electromyography (EMG) and motion sensor data to provide accurate long-term insight into motor symptoms typical of Parkinson’s disease. Adamant Health is the only provider in the world of this type of technology, which can be used in clinical patient care in clinics, as well as at home.

Adamant Health, Gerresheimer, Dietmar Siemssen“We see great opportunities in our partnership with Adamant Health. Our common goal is to optimize the personalized treatment of Parkinson’s disease and to significantly improve the patient’s quality of life,” said Dietmar Siemssen, CEO of Gerresheimer AG.

“Our investment will help drive the development of Adamants’ unique technology and service. At the same time, it is part of our strategic expansion into innovative platform-based drug delivery devices and digital disease monitoring.”

To date, Adamant Health has raised a total of €2.2 million for its funding round and is still seeking €800,000 to complete the round. With this investment, the Adamant Health team is able to pursue its ultimate goal: to see the technology widely used in Parkinson’s care, research and pharmaceutical companies for the benefit of all people with Parkinson’s disease. of Parkinson’s disease.

Click here to read more funding news.